MolMed
Biotechnology company founded in 1996 in Milan
MOLMED is an Italian biotechnology company founded in 1996 in Milan, where it has its registered and operational headquarters. It originally operated as a contract manufacturing organization, and provided other services for companies developing gene therapy and cell therapy products. In 2000, the company changed its business model and started to develop products of its own. It is now focused on research, development, and clinical validation of innovative therapies for the treatment of cancer.
Its headquarters are located within the San Raffaele Biomedical Science Park (which includes the hospital of the same name, a research institute, and a private university), and an operational site in Bresso at OpenZone.
History
The company was founded by Claudio Bordignon in 1996 as a joint venture between Science Park Raf and Boehringer Mannheim.
During its first three years, during which the acquisition of Boehringer Mannheim by Roche took place, Roche sold its stake in MolMed to the venture capital fund EDCP.
In 2001, MolMed signed an agreement with San Raffaele Hospital which gave MolMed an option to license any gene therapy or cell therapy invention made at the hospital in the fields of cancer and HIV.
In 2002 the company acquired and incorporated Genera S.p.A., the research company of the San Raffaele Scientific Institute, and in 2004 three major Italian private investors joined MolMed's shareholder base: Fininvest, Herule Finance (later H-Equity S.r.l.), and La Leonardo Finanziaria (now Delfin S.à r.l.), through a capital increase of 20 million euros.
In 2006 a capital increase of 16 million euros took place and in 2007 another of 10 million euros, leading up to the company's stock market listing in 2008 with a public offering (IPO) of 25% of its shares, through which 56 million euros were raised before expenses. The total number of shares issued was 105,207,808 (100% ordinary shares without nominal value).
Finally, in 2010 a rights issue capital increase was carried out (58 million euros before expenses), with one new share issued for each share outstanding, for a total of 210,415,616 shares issued (100% ordinary shares without nominal value).
Begin with the source’s own compact description: “MolMed” is biotechnology company founded in 1996 in Milan. The dossier treats that line as a proposition to test through MolMed, Biotechnology and company, not as a finished interpretation.
Why this record matters
The phrase “biotechnology company founded in 1996 in Milan” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Chronology, provenance and viewpoint should be read together before a broad social or political interpretation is accepted. The source revision retrieved here is dated Jul 16, 2026. The linked authority identifier is Q17113918. 2 of 2 selected statements include explicit references; 0 carry qualifiers and 0 use preferred rank. The first chronological checks are 1996, 2000, 2001 and 2002.
Official terminology may obscure informal participation, dissent or communities documented only indirectly. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Compare institutional narratives with records created by participants and affected communities. Dates and formal titles are useful anchors, but not substitutes for context.
- Event chronology
- Institutional context
- Locating named record creators
Contemporary correspondence, government or organizational records, oral histories and cited historical scholarship.
Three-step research path
- Establish the record: confirm the title “MolMed”, its source revision and the description used here.
- Expand the search: follow MolMed primary sources, MolMed archive and MolMed research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “MolMed”?
- What chronology connects this entry to wider political or social change?
- Who created the surviving record, and for what administrative purpose?
Search terms from this dossier
This entry incorporates text from “MolMed” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.